Four DLBCL cell lines, Su-6, Su-8, Su-10, and DoHH2, were treated with 3 different doses of CHOP and/or 10 μg/ml of rituximab for 24 hours. Here, DDIT3 is linked to diffuse large B-cell lymphoma.